DDRI-18

• Description :

  DDRI-18 is a DNA damage response inhibitor that inhibits the non-homologous end-joining (NHEJ) DNA repair process. DDRI-18 is an effective chemosensitizing agent[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H315-H319-H335-H413

• Target :

  DNA/RNA Synthesis

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/ddri-18.html

• Solubility :

  10 mM in DMSO

• Smiles :

  NC1=CC=CC(C2=NC3=CC=C(C=C3N2)C4=CC=C5N=C(NC5=C4)C6=CC(N)=CC=C6)=C1

• Molecular Formula :

  C26H20N6

• Molecular Weight :

  416.48

• Precautions :

  P261-P264-P271-P273-P280-P302+P352-P304+P340-P305+P351+P338-P362+P364-P403+P233-P405-P501

• References & Citations :

  [1]D W Jun, et al. Characterization of DDRI-18 (3,3'- (1H,3'H-5,5'-bibenzo[d]imidazole-2,2'-diyl) dianiline), a novel small molecule inhibitor modulating the DNA damage response. Br J Pharmacol. 2012 Sep;167 (1) :141-50.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [4402-18-0]